racemetirosine has been researched along with Cancer of Larynx in 1 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henze, M | 1 |
| Mohammed, A | 1 |
| Mier, W | 1 |
| Rudat, V | 1 |
| Dietz, A | 1 |
| Nollert, J | 1 |
| Eisenhut, M | 1 |
| Haberkorn, U | 1 |
1 trial available for racemetirosine and Cancer of Larynx
| Article | Year |
|---|---|
Pretreatment evaluation of carcinomas of the hypopharynx and larynx with 18F-fluorodeoxyglucose, 123I-alpha-methyl-L-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile.
Topics: alpha-Methyltyrosine; Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Hypopharyngeal Neoplasms; I | 2002 |